Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease
We report the efficacy and safety of cinacalcet for treatment of refractory secondary hyperparathyroidism (SHPT) in children with ESKD. After 6 months of cinacalcet treatment, the mean level of iPTH serum level decreased by 56% from 202 pmol/L [95% confidence interval (CI): 150-253] to 88 pmol/L (95% CI: 41-136), compared to the change observed in the control group (P <0.001). None of our patients reported serious adverse effects or developed hypocalcemia. Cinacalcet could be an effective and safe alternative to treat severe SHPT in children with ESKD. Further long-term and large-scale studies are necessary to confirm i...
Source: Saudi Journal of Kidney Diseases and Transplantation - August 10, 2022 Category: Urology & Nephrology Authors: Areej Adel Sheerah Rafif Ali Al-Ahmed Sherif M El-Desoky Khalid Abdulaziz Alhasan Amr S Albanna Mohamed A Shalaby Jameela Abdulaziz Kari Source Type: research
